Platinum Nanorods are elongated particles ranging from 10 to 120 nanometers (nm) with specific surface area (SSA) in the 30 - 70 m 2 /g range. Nano Platinum is also available passivated and in Ultra high purity and high purity and coated and dispersed forms. They are also available as a nanofluid through the AE Nanofluid production group. Nanofluids are generally defined as suspended nanorods in solution either using surfactant or surface charge technology. Nanofluid dispersion and coating selection technical guidance is also available. Other nanostructures include nanoparticles, nanowhiskers, nanohorns, nanopyramids and other nanocomposites. Surface functionalized nanorods allow for the particles to be preferentially adsorbed at the surface interface using chemically bound polymers. Development research is underway in Nano Electronics and Photonics materials, such as MEMS and NEMS, Bio Nano Materials, such as Biomarkers, Bio Diagnostics & Bio Sensors, and Related Nano Materials, for use in Polymers, Textiles, Fuel Cell Layers , Composites and Solar Energy materials. Nanopowders are analyzed for chemical composition by ICP, particle size distribution (PSD) by laser diffraction, and for Specific Surface Area (SSA) by BET multi-point correlation techniques. Novel nanotechnology applications also include Quantum Dots . High surface areas can also be achieved using solutions and using thin film by sputtering targets and evaporation technology using pellets, rod and foil. Applications for Platinum nanorods generally involve their magnetic properties and include in catalysts and magnetic recording and in medical sensors and bio medicine as a contrast enhancement agent for magnetic resonance imaging (MRI). Platinum particles are being tested for site specific drug delivery agents for cancer therapies and in coatings, plastics, nanowire, nanofiber and textiles and in certain alloy and catalyst applications . Further research is being done for their potential electrical, dielectric, magnetic, optical, imaging, catalytic, biomedical and bioscience properties. Platinum Nano Particles are generally immediately available in most volumes. Additional technical, research and safety (MSDS) information is available.
Platinum is a Block D, Group 10, Period 6 element. The electronic configuration is Xe] 4f14 5d9 6s1. In its elemental form platinum's CAS number is 7439-88-5. The platinum atom has a radius of 137.3.pm and it's Van der Waals radius is 172.pm. Platinum is a member of the platinum group of metals. It is highly corrosion resistant and has numerous catalytic applications. These include in petrochemical cracking catalysts, automotive catalytic converters and in the processes used for proton exchange membrane fuel cells. The metal does not oxidize in air at any temperature. The metal is extensively used in jewelry, electronic wire, and crucibles for corrosive and high temperature laboratory uses and in many advanced instruments. Platinum compounds have application in medicine. Platinum is available as metal and compounds with purities from 99% to 99.999% (ACS grade to ultra-high purity); metals in the form of foil, sputtering target, and rod, and compounds as submicron and nanopowder. Platinum was first discovered by Julius Scaliger in 1735.
|
| |
Periodic table of the elements science and academic information, elements and advanced materials data, scientific presentations and all pages, designs, concepts, logos, and color schemes herein are the copyrighted proprietary rights and intellectual property of American Elements. American Elements is a U.S. Registered Trademark. © 2001-2009. American Elements. All rights reserved. |
 |
|
Recent Research & Development for Platinum
-
Platinum-catalysed aerobic 1,2-aminooxygenation of alkenes.
Muñiz K, Iglesias A, Fang Y.
Chem Commun (Camb). 2009 Oct 7;(37):5591-3. Epub 2009 Aug 28.
PMID: 19753367 [PubMed - in process]
- Treatment of recurrent epithelial ovarian cancer.
Pisano C, Bruni GS, Facchini G, Marchetti C, Pignata S.
Ther Clin Risk Manag. 2009 Aug;5(4):421-6. Epub 2009 Jun 22.
PMID: 19753136 [PubMed - in process]
- Oestrogen receptor 1 mRNA is a prognostic factor in ovarian cancer patients treated with neo-adjuvant chemotherapy: determination by array and kinetic PCR in fresh tissue biopsies.
Zamagni C, Wirtz R, De Iaco P, Rosati M, Veltrup E, Rosati F, Capizzi E, Cacciari N, Alboni C, Bernardi A, Massari F, Quercia S, D'Errico Grigioni A, Dietel M, Sehouli J, Denkert C, Martoni A.
Endocr Relat Cancer. 2009 Sep 11. [Epub ahead of print]
PMID: 19749010 [PubMed - as supplied by publisher]
- Studies on the Synthesis and Activity of Three Tripalladium Complexes Containing Planaramine Ligands.
Farhad M, Yu JQ, Beale P, Fisher K, Huq F.
ChemMedChem. 2009 Sep 10. [Epub ahead of print]
PMID: 19746359 [PubMed - as supplied by publisher]
- Differences in the Expression Profiles of Excision Repair Crosscomplementation Group 1, X-Ray Repair Crosscomplementation Group 1, and betaIII-Tubulin Between Primary Non-small Cell Lung Cancer and Metastatic Lymph Nodes and the Significance in Mid-Term Survival.
Kang CH, Jang BG, Kim DW, Jeong DH, Kim YT, Jheon S, Sung SW, Kim JH.
J Thorac Oncol. 2009 Sep 10. [Epub ahead of print]
PMID: 19745766 [PubMed - as supplied by publisher]
- Efficacy and Toxicity of Belotecan With and Without Cisplatin in Patients With Recurrent Ovarian Cancer.
Nam EJ, Kim JW, Kim JH, Kim S, Kim SW, Jang SY, Lee DW, Jung YW, Kim YT.
Am J Clin Oncol. 2009 Sep 10. [Epub ahead of print]
PMID: 19745693 [PubMed - as supplied by publisher]
- Immobilization of glucose oxidase on a poly(dimethylsiloxane) layer by using poly(L-lysine) as a polymer backbone.
Yasukawa T, Maekawa E, Mizutani F.
Anal Sci. 2009 Sep;25(9):1159-62.
PMID: 19745547 [PubMed - in process]
- Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.
Park SB, Lin CS, Krishnan AV, Goldstein D, Friedlander ML, Kiernan MC.
Brain. 2009 Sep 10. [Epub ahead of print]
PMID: 19745023 [PubMed - as supplied by publisher]
- Combined Low Temperature Rapid Scan and (1)H NMR Mechanistic Study of the Protonation and Subsequent Benzene Elimination from a (Diimine)platinum(II) Diphenyl Complex Relevant to Arene C-H Activation.
Parmene J, Ivanovic´-Burmazovic´ I, Tilset M, van Eldik R.
Inorg Chem. 2009 Sep 10. [Epub ahead of print]
PMID: 19743822 [PubMed - as supplied by publisher]
- Functional glutathione S-transferase genotypes among testicular germ cell tumor survivors: associations with primary and post-chemotherapy tumor histology.
Kraggerud SM, Oldenburg J, Alnaes GI, Berg M, Kristensen VN, Fossa SD, Lothe RA.
Pharmacogenet Genomics. 2009 Sep 8. [Epub ahead of print]
PMID: 19741569 [PubMed - as supplied by publisher]
- Histological response is not a prognostic factor after neoadjuvant chemotherapy in advanced-stage ovarian cancer with no residual disease.
Ferron JG, Uzan C, Rey A, Gouy S, Pautier P, Lhommé C, Duvillard P, Morice P.
Eur J Obstet Gynecol Reprod Biol. 2009 Sep 7. [Epub ahead of print]
PMID: 19740592 [PubMed - as supplied by publisher]
- Development of a Titanium Dioxide-Supported Platinum Catalyst with Ultrahigh Stability for Polymer Electrolyte Membrane Fuel Cell Applications.
Huang SY, Ganesan P, Park S, Popov BN.
J Am Chem Soc. 2009 Sep 9. [Epub ahead of print]
PMID: 19739667 [PubMed - as supplied by publisher]
- Gefitinib: a second look. Non-small cell lung cancer: still very disappointing.
[No authors listed]
Prescrire Int. 2009 Aug;18(102):145-7.
PMID: 19739343 [PubMed - in process]
- Randomized, Placebo-Controlled, Phase II Study of Sequential Erlotinib and Chemotherapy As First-Line Treatment for Advanced Non-Small-Cell Lung Cancer.
Mok TS, Wu YL, Yu CJ, Zhou C, Chen YM, Zhang L, Ignacio J, Liao M, Srimuninnimit V, Boyer MJ, Chua-Tan M, Sriuranpong V, Sudoyo AW, Jin K, Johnston M, Chui W, Lee JS.
J Clin Oncol. 2009 Sep 8. [Epub ahead of print]
PMID: 19738125 [PubMed - as supplied by publisher]
- Safety of Bevacizumab in Patients With Non-Small-Cell Lung Cancer and Brain Metastases.
Socinski MA, Langer CJ, Huang JE, Kolb MM, Compton P, Wang L, Akerley W.
J Clin Oncol. 2009 Sep 8. [Epub ahead of print]
PMID: 19738122 [PubMed - as supplied by publisher]
- Current data of targeted therapies for the treatment of triple-negative advanced breast cancer: empiricism or evidence-based?
Petrelli F, Cabiddu M, Ghilardi M, Barni S.
Expert Opin Investig Drugs. 2009 Sep 8. [Epub ahead of print]
PMID: 19737114 [PubMed - as supplied by publisher]
- Fabrication of TiO(2) and Metal Nanoparticle-Microelectrode Arrays by Photolithography and Site-Selective Photocatalytic Deposition.
Li X, Tian Y, Xia P, Luo Y, Rui Q.
Anal Chem. 2009 Sep 8. [Epub ahead of print]
PMID: 19736965 [PubMed - as supplied by publisher]
- Carbon on Platinum Substrates: From Carbidic to Graphitic Phases on the (111) Surface and on Nanoparticles (dagger).
Vin~es F, Neyman KM, Go¨rling A.
J Phys Chem A. 2009 Sep 8. [Epub ahead of print]
PMID: 19736956 [PubMed - as supplied by publisher]
- Urinary excretion of carnitine as a marker of proximal tubular damage associated with platin-based antineoplastic drugs.
Haschke M, Vitins T, Lüde S, Todesco L, Novakova K, Herrmann R, Krähenbühl S.
Nephrol Dial Transplant. 2009 Sep 7. [Epub ahead of print]
PMID: 19736245 [PubMed - as supplied by publisher]
- Mechanism of Enhanced Electrochemical Oxidation of 2,4-dichlorophenoxyacetic Acid with in situ Microwave Activated Boron-doped Diamond and Platinum Anodes.
Gao J, Zhao G, Liu M, Li D.
J Phys Chem A. 2009 Sep 8. [Epub ahead of print]
PMID: 19735119 [PubMed - as supplied by publisher]
|
|